Neutrophil-Derived MMP9: A New Target in Rapid Antidepressant Action

Neutrophil-Derived MMP9 Is Essential for Rapid Antidepressant Effects

Recent preclinical research, published on November 9, 2026 (OpenAlex W7225643687), demonstrates that matrix metalloproteinase-9 (MMP9) produced by peripheral neutrophils is a critical mediator of the rapid antidepressant effects observed with compounds such as 2,5-dimethoxy-4-methylamphetamine (DOM) and ketamine. The study integrates single-cell transcriptomics, functional cell assays, a Transwell blood–brain barrier (BBB) model, and three distinct mouse models of depression to systematically dissect the immune mechanisms underlying these effects. The findings highlight that brain-resident cells express minimal MMP9, and that antidepressant efficacy depends on the functional status of circulating neutrophils, not on direct brain infiltration.

Mechanistic Insights: From Peripheral Immune State to Brain Plasticity

The mechanism by which DOM and ketamine exert rapid antidepressant effects involves the activation of the PI3K-Akt signaling pathway in neutrophils, prompting a shift toward an N2 anti-inflammatory phenotype and a moderate increase in MMP9 production. Under homeostatic conditions, MMP9 crosses the BBB via caveolin-1-mediated transcytosis in endothelial cells, a process that does not disrupt tight junctions or require neutrophil migration into the brain. Once in the brain, MMP9 degrades perineuronal nets (PNNs), facilitating dendritic spine plasticity and restoring gamma-oscillation circuit function—both considered hallmarks of antidepressant efficacy.

Importantly, the study reveals a non-obvious regulatory axis: the efficacy of rapid-acting antidepressants is strictly contingent on the balance of neutrophil activity. Suppressing neutrophil function depletes peripheral MMP9, blunting drug response, while hyperactivation leads to neurotoxic MMP9 levels and reduced efficacy, both reversible by modulating MMP9 availability. This suggests that immune profiling—specifically, neutrophil state—could serve as a predictive biomarker for treatment response, a criterion rarely considered in current clinical trial designs for psychedelics or rapid-acting antidepressants.

Policy and Research Implications: Toward Precision Psychiatry

These findings have significant implications for the design of future clinical trials and the development of individualized treatment strategies in psychiatry. Current regulatory and research paradigms for psychedelic and rapid-acting antidepressants, such as those overseen by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), generally do not stratify participants by immune status or neutrophil function. The identification of neutrophil-derived MMP9 as a mechanistic link between peripheral immunity and central nervous system (CNS) plasticity suggests that immune subtyping could improve trial efficiency and outcome prediction.

• Biomarker Development: Peripheral MMP9 levels and neutrophil phenotyping could be incorporated into early-phase (Phase I/II) trials to identify likely responders and non-responders, reducing heterogeneity and improving statistical power.
• New Molecular Targets: The study highlights MMP9 and its regulatory pathways as potential drug targets, not only for depression but also for other neuropsychiatric conditions where plasticity deficits are implicated.
• Individualized Approaches: Immune profiling may enable precision interventions, tailoring treatments to patients' baseline immune states—an approach that could be extended to other psychiatric indications.

Notably, this research also raises questions about the adequacy of exclusion criteria in current trials, as participants with altered neutrophil function (due to infection, autoimmune disease, or medication) may respond differently to rapid-acting antidepressants.

Risks, Unknowns, and Potential Failure Modes

While the study offers compelling mechanistic insights, several risks and unknowns must be addressed before translation to clinical practice. The findings are based on preclinical mouse models and in vitro systems; human immune-brain interactions are more complex and may not fully recapitulate these mechanisms. Excessive or dysregulated MMP9 activity is associated with neurotoxicity and blood–brain barrier disruption in other contexts, raising safety concerns if this pathway is pharmacologically targeted or manipulated.

Another practical consideration is the dynamic nature of neutrophil function, which can be influenced by acute illness, chronic inflammation, or concomitant medications. This introduces a real-world failure mode: patients with fluctuating immune status may experience variable efficacy or adverse effects, complicating both clinical management and trial interpretation. The study’s demonstration that hippocampal MMP9 replenishment can rescue antidepressant response in neutrophil-suppressed mice is promising but may not be directly translatable to humans without further safety and delivery research.

Outlook: Integrating Immune Profiling into Psychedelic and Antidepressant Research

The identification of neutrophil-derived MMP9 as a key mediator of rapid antidepressant effects marks a significant advance in our understanding of the interface between the immune system and brain plasticity. For researchers and clinicians, the next step is to validate these findings in human studies and to explore the feasibility of incorporating immune biomarkers into trial protocols. For policymakers and regulators, updating guidance to reflect these mechanistic insights could accelerate the development of precision psychiatry approaches, ultimately improving outcomes for patients with depression and related disorders.

Byline: Dr. Alex Chen, MD, PhD — Neuroscience EditorHow we research: This article was reviewed by Dr. Alex Chen on 2026-11-10, referencing the original OpenAlex publication and primary preclinical data.